Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 539730 | NSE Symbol : | ISIN : INE194R01017 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
22-Jan-2025	04-Feb-2025	Quarterly Results	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 inter alia to consider and approve Prior Intimation for the Board Meeting of the Company to be held on Tuesday 04th February 2025. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, February 04, 2025 has inter-alia, considered, adopted and approved following items of business: 1. In compliance to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter Ended 31st December, 2024 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditors of the Company; copies of which are attached hereunder; 2.Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held today has ratified incorporation of a Wholly Owned Subsidiary ('WOS') with the name as Fredun Retail Private Limited as approved by the Ministry of Corporate Affairs, Government of India. (As Per Bse Announcement Dated on 04.02.2025)
15-Oct-2024	26-Oct-2024	Quarterly Results	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2024 inter alia to consider and approve 1. To discuss consider and approve Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30 2024. OUTCOME OF THE BOARD MEETING HELD ON SATURDAY 26TH OCTOBER, 2024 (As Per BSE Announcement Dated on: 26/10/2024)
26-Sep-2024	03-Oct-2024	Issue of FCCB	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/10/2024 inter alia to consider and approve We wish to inform you that pursuant to Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 a meeting of the Board of Directors (the 'Board') of Fredun Pharmaceuticals Limited (the 'Company') is scheduled to be held on Thursday 03rd October 2024 to inter alia consider issue and allotment of Unsecured Foreign Currency Convertible Bonds (FCCBs) in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 and the Companies Act 2013 and any other regulations and rules as applicable as amended subject to such regulatory/ statutory approvals as may be required. Issue of FCCBs Issue of 100 (One Hundred) Unsecured Foreign Currency Convertible Bonds of an aggregate principal amount of USD 10,000,000 (Ten Million United States Dollars) at an Issue Price of USD 100,000 (One Hundred Thousand United States Dollars) each at zero coupon and an aggregate yield to maturity of 7% (Seven Per Cent.), with a maturity tenure of 10 (Ten) years and 1 (One) day due October 04, 2034, on private placement basis to Amicorp Capital (Mauritius) Limited. The Company, at its discretion, may issue a further 20 (Twenty) Unsecured Foreign Currency Convertible Bonds of an aggregate amount of USD 2,000,000 (Two Million United States Dollar) ('Green Shoe Option') within 30 (thirty) days from the closing date. (As Per BSE Announcement dated on 03.10.2024)
20-Jul-2024	29-Jul-2024	Quarterly Results	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 inter alia to consider and approve Notice is hereby given pursuant to Reg 29 read with Regulation 33 of SEBI (LODR) Reg 2015 that the meeting of the Board of Directors of Fredun Pharmaceuticals Limited is scheduled to be held on Monday 29th July 2024 inter alia to consider and approve the following: 1. To discuss consider and approve Unaudited Financial Results of the Company for the Quarter ended June 30 2024. 2. Any other matter with the permission of the Chair. Further in continuation of our intimation dated June 27 2024 and pursuant to Companys Code of Conduct formed under the SEBI (PIT ) Regulations 2015 and amendments thereunder the trading window for dealing in the securities of the Company has been closed from July 01 2024 and it shall remain closed until forty-eight hours after the date of declaration of results for the Quarter ended June 30 2024. The same has been circulated to the Directors Key Managerial Personnel Employees of the Company and their immediate relatives. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, July 29, 2024 has inter-alia, considered, adopted and approved following items of business: 1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter Ended 30th June, 2024 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditors of the Company; copies of which are attached hereunder; In furtherance to the intimation filed by the Company dated June 27, 2024; the trading window for trading in securities of the Company by insiders closed on July 01, 2024 till the end of 48 hours after the declaration of outcome of Board Meeting. The Board Meeting commenced at 04:00 p.m. and concluded at 07:15 p.m Outcome of Board Meeting along with financial Results for the quarter ended 30th June, 2024 (As per BSE Announcement Dated on 29/07/2024)
24-Apr-2024	07-May-2024	Accounts	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2024 inter alia to consider and approve Notice is hereby given pursuant to Regulation 29 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that the meeting of the Board of Directors of Fredun Pharmaceuticals Limited is scheduled to be held on Tuesday 07th May 2024 inter alia to consider and approve the following: 1. Consider and approve Audited Financial Results for the Financial Year ended March 31 2024 along with the Statement of Assets and Liabilities and Cash Flow statement as on that date. 2. Consider and recommend final dividend on the paid-up equity shares for the Financial Year ended March 31 2024. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, May 07, 2024 has inter-alia, considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 2024 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. Enclosed are: a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Recommended Final Dividend at 7% per Equity Share having Face Value of Rs. 10/- each for the Financial Year 2023-24; subject to the approval of the Shareholders at the ensuing 37th Annual General Meeting of the Company; Revised outcome for the Board Meeting Dated 07.05.2024 Revised Financial Resuls (As per BSE Announcement Dated on 07/05/2024)
15-Apr-2024	15-Apr-2024	Conversion	Allotment of 20,000 Equity Shares to Non-Promoter upon conversion of Warrants into Equity Shares
22-Mar-2024	22-Mar-2024	Conversion	This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotment of convertible warrants on preferential basis to Non-promoters on March 22, 2024. Further, we would like to inform that the Warrant Holder have paid the balance of the consideration aggregating to Rs 12,45,250/- and have applied for exercising their rights for conversion of 2,500 warrants into equivalent number of equity Shares.
05-Feb-2024	14-Feb-2024	Quarterly Results	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve To discuss consider and approve Unaudited Financial Results of the Company for the Quarter and Nine Months ended 31St Decembers 2023. We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Wednesday, 14 February, 2024 had considered and approved the following item: 1. In compliance to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter and Nine months ended 31st December, 2023 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 02:00 P.M. and concluded at 07:00 P.M. (As Per BSE Announcement dated on 14.02.2024)
21-Dec-2023	21-Dec-2023	Change in Directors	Re-appointment of Dr. (Mrs) Daulat Medhora as a Whole time Director designated as Jt Managing Director for the period of 5 years w.e.f 31st December, 2023 We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Thursday, December, 21 2023 had considered and approved the re-appointment of Dr. (Mrs) Daulat Nariman Medhora (DIN: 01745277) as the Whole time Director designated as Jt Managing Director of the Company for a further term of five years w.e.f. December 31, 2023 to December 30, 2028. The brief profile of Dr. (Mrs.) Daulat Medhora (DIN: 01745277) and disclosures as required is enclosed herewith as 'ANNEXURE A'''. to this intimation. The Meeting of the Board Commenced at 06.00 P.M. and concluded at 06:20 P.M.
08-Dec-2023	16-Dec-2023	Raising funds through Debt Instr.	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/12/2023 inter alia to consider and approve for fund raising upto Rs. 120 crores by way of further public offer right issue ADR/GDR/FCCB QIP Debt issue preferential issue or any other method. FREDUN PHARMACEUTICALS LIMITED has informed BSE about Board Meeting to be held on 16 Dec 2023 to consider Fund raising. 1. To consider a proposal for fund raising up to Rs.120 crores by way of further public offer, rights issue, American Depository Receipts/Global Depository Receipts/Foreign Currency Convertible Bonds, qualified institutions placement, debt issue, preferential issue or any other method, in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013 and any other regulations and rules as applicable, as amended subject to such regulatory/ statutory approvals as may be required. 2. The Information required to be submitted pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13,2023 is annexed herewith as Annexure I. The meeting commenced at 03:00 pm and concluded at 06:30 pm. To consider a proposal for Fund raising upto Rs. 120 Crores by way of FPO, Right issue, ADR/GDR/FCCB, QIP, Debt Issue, Preferential issue or any other method in accordance with the provisions applicable (As Per BSE Announcement dated on 16.12.2023)
05-Dec-2023	05-Dec-2023	Conversion	This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotment of convertible warrants on preferential basis to Promoters and Non-promoters on October 15, 2022. Further, we would like to inform that the Warrant Holder have paid the balance of the consideration aggregating to Rs. 24,90,500/- and have applied for exercising their rights for conversion of 5,000 warrants into equivalent number of Equity Shares.
24-Nov-2023	24-Nov-2023	Change in Directors	Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ('Listing Regulations'), we would like to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors have, vide Resolution dated 24th November, 2023, have appointed Ms. Daisy Cyril Dsouza (DIN: 09348309) as an Additional Director in the category of Independent Director of the Company for a term of five years with effect from 24th November, 2023 subject to the approval of shareholders.
10-Nov-2023	10-Nov-2023	Conversion	This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotment of convertible warrants on preferential basis to Promoters on October 15, 2022. Further, we would like to inform that the Warrant Holder have paid the balance of the consideration aggregating to Rs. 50,00,000/- and have applied for exercising their rights for conversion of 10,000 warrants into equivalent number of Equity Shares
31-Oct-2023	08-Nov-2023	Quarterly Results	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve Pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday 08th November2023 at 11.00 a.m. to transact inter - alia the following businesses: 1) To discuss consider and approve Unaudited Financial Results of the Company for the Quarter and half year ended 30th September 2023. 2) To re-appoint Mr. Fredun Nariman Medhora (DIN: 01745348) as the Managing Director for a further term of five years with. The Board Meeting to be held on 08/11/2023 has been revised to 08/11/2023 The Board Meeting to be held on 08/11/2023 at 11 am has been revised to 08/11/2023 at 3 pm (As Per BSE Announcement Dated on 06.11.2023) 1. In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirement) Requirements 2015 the un-audited financials for the quarter and half year ended 30th September,2023 along with limited review report as issued by M/s. RH Nisar & Co. Statutory Auditors of the Company. 2. Re-appointment of Mr. Fredun Medhora as the Managing Director of the Company for a further period of five years wef 15.10.2023 to 14.10.2028 The meeting of the board commenced at 03:00 pm and concluded at 07:00 pm (As per BSE Announcement Dated on 08/11/2023)
22-Sep-2023	22-Sep-2023	Conversion	This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotment of convertible warrants on preferential basis to Promoters on October 15, 2022. Further, we would like to inform that the Warrant Holders have paid the balance of the consideration aggregating to Rs. 1,42,49,526/- and have applied for exercising their rights for conversion of 19,072 warrants into equivalent number of Equity Shares. Consequently, the Board of Directors in its meeting held on i.e. September 22, 2023 has allotted 19,072 Equity Shares of face value Rs. 10/- each to the warrant holder

1 2 3

LOGIN HERE

Fredun Pharmaceuticals Ltd

Board Meeting